Colistin<i>vs</i>. the combination of colistin and rifampicin for the treatment of carbapenem-resistant<i>Acinetobacter baumannii</i>ventilator-associated pneumonia
抄録
<jats:title>SUMMARY</jats:title><jats:p>The aim of this study was to compare the responses of colistin treatment alone<jats:italic>vs</jats:italic>. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant<jats:italic>A. baumannii</jats:italic>strain. Forty-three patients were randomly assigned to one of two treatment groups. Although clinical (<jats:italic>P</jats:italic> = 0·654), laboratory (<jats:italic>P</jats:italic> = 0·645), radiological (<jats:italic>P</jats:italic> = 0·290) and microbiological (<jats:italic>P</jats:italic> = 0·597) response rates were better in the combination group, these differences were not significant. However, time to microbiological clearance (3·1 ± 0·5 days,<jats:italic>P</jats:italic> = 0·029) was significantly shorter in the combination group. The VAP-related mortality rates were 63·6% (14/22) and 38·1% (8/21) for the colistin and the combination groups (<jats:italic>P</jats:italic> = 0·171), respectively. Our results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with<jats:italic>A. baumannii</jats:italic>.</jats:p>
収録刊行物
-
- Epidemiology and Infection
-
Epidemiology and Infection 141 (6), 1214-1222, 2012-09-07
Cambridge University Press (CUP)
